Oncology Drugs Global Market Report 2018

1
OYÐolog? Drugs Glodal Market Report ????
Including Blood CaYÐer Breast CaYÐer CeriÐal
CaYÐer LuYg CaYÐer ColoreÐtal CaYÐer NoY-Swall
Cell LuYg CaYÐer Prostate CaYÐer KidYe? CaYÐer
PaYÐreatiÐ CaYÐer BraiY Tuwor GastriÐ CaYÐer
SkiY CaYÐer OariaY CaYÐer Bladder CaYÐer
Th?roid CaYÐer Others Kaposi SarÐowa,
AIDS-Related L?wphowa, AYal CaYÐer, BoYe CaYÐer,
RetiYodlastowa, TestiÐular CaYÐer, HepatoÐellular
Lier? CaYÐer, Mouth CaYÐer, Neurodlastowa?
Covering F. HoffwaYY-La RoÐhe Ltd, Noartis AG,
Gilead SÐieYÐes IYÐ., Ba?er AG, Takeda
PharwaÐeutiÐals
Fed ????
2

• Reasons to Purchase
• Outperform competitors using accurate up to date
  demand-side dynamics information.
• Identify growth segments for investment.
• Facilitate decision making on the basis of
  historic and forecast data and the drivers and
  restraints on the market.
• Create regional and country strategies on the
  basis of local data and analysis.
• Stay abreast of the latest customer and market
  research findings
• Benchmark performance against key competitors.
• Develop strategies based on likely future
  developments.
• Utilize the relationships between key data sets
  for superior strategizing.
• Suitable for supporting your internal and
  external presentations with reliable high quality
  data and analysis
• Gain a global perspective on the development of
  the market.
• Report will be updated with the latest data and
  delivered to you within 3-5 working days of
  order.
• Scope
• Markets Covered Blood Cancer Breast Cancer
  Cervical Cancer Lung Cancer Colorectal Cancer
  Non-Small Cell Lung Cancer Prostate Cancer
  Kidney Cancer Pancreatic Cancer Brain Tumor
  Gastric Cancer Skin Cancer Ovarian Cancer
  Bladder Cancer Thyroid Cancer Others (Kaposi
  Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone
  Cancer, Retinoblastoma, Testicular Cancer,
  Hepatocellular (Liver) Cancer, Mouth Cancer,
  Neuroblastoma)
• Companies Mentioned F. Hoffmann-La Roche Ltd,
  Novartis AG, Gilead Sciences Inc., Bayer AG,
  Takeda Pharmaceuticals
• Countries Brazil, China, France, Germany, India,
  Italy, Japan, Spain, Russia, UK, USA and
  Australia.

3
Oncology Drugs Market Characteristics

• Oncology deals with diagnosis, prevention and
  treatment of cancer diseases. Anti- cancer or
  anti-neoplastic agents are the drugs that prevent
  or inhibit or halt the proliferation and
  maturation of neoplasms, an abnormal growth
  of tissues commonly referred as tumors.
  These drugs prevent the growth of malignant
  tumors by affecting the process of cell division
  or by damaging the DNA and initiate apoptosis or
  by preventing the development and spread of
  neoplastic cells. Several types of cancers that
  can be treated by oncology drugs are blood
  cancer, lung cancer, endocrine cancer, bone
  cancer, gastric cancer, colorectal cancer,
  skin cancer, breast cancer, pancreatic cancer,
  prostate cancers, ovarian cancer, ocular cancer
  and others.
• The market numbers within this briefing are
  restricted to pharmaceutical (drug) treatments
  and do not cover biologic treatments for these
  conditions which are included in a separate
  briefing. Based on the type and stage of cancer,
  treatment options include Surgery, Radiation
  therapy, chemotherapy, immunotherapy,
  targeted therapy, hormone therapy, and stem
  cell transplant. In most cases, a
  combination of more than one type of treatment is
  chosen. Treatment with drugs include the
  following categories
• Chemotherapy Drugs are the medications
  used for cancer treatment. They function by
  inhibiting cell division or
• Immunotherapy Or Biologic Therapy Or Biotherapy
  Drugs
• Targeted Therapy Drugs
• Hormone Therapy
• Stem Cell Transplants

4
The oncology drugs market data is segmented
based on the actual usage for diseases, as
follows

Blood Cancer Drugs Breast Cancer Drugs Cervical
Cancer Drugs Lung Cancer Drugs Colorectal Cancer
Drugs Non-Small Cell Lung Cancer Drugs Prostate
Cancer Drugs Kidney Cancer Drugs Gastric Cancer
Drugs Brain Tumor Drugs Pancreatic Cancer Drugs
Skin Cancer Drugs Ovarian Cancer Drugs Bladder
Cancer Drugs Thyroid Cancer Drugs Others (Kaposi
Sarcoma, AIDS-Related
Lymphoma, Anal Cancer, Bone
Cancer, Retinoblastoma, Testicular Cancer,
Hepatocellular (Liver) Cancer, Mouth Cancer,
Neuroblastoma) However, some of the drugs are
used for one or more types of cancers. In this
report market value is defined as the revenues
organizations earn by selling their goods and
services within the specified market, based on
the price at which they sell. Only goods and
services traded between entities are
included. The revenues for a specified geography
are consumption values that is, they are
revenues generated by organizations in the
specified geography within the specified
market, irrespective of where they are produced.
5
Oncology Drugs Market Historic Growth
The global oncology drugs market grew from X
billion in 2013 to X billion in 2017 at a
compound annual growth rate (CAGR) of X. The
chart and table below shows the year-on-year
growth of the global oncology drugs market during
2013 2017.
Drivers of the Market Restraints on the Market
6
Oncology Drugs Market Forecast Growth
The global Oncology Drugs market grew from XX
billion in 2017 to 165.00 billion in 2021 at a
compound annual growth rate (CAGR) of XX. The
oncology drugs market is expected to grow
due to the increasing number of expensive
but advanced and effective medications that will
help in increasing the life expectancy of ÐaYÐer
patieYts. For e?awple, iY ????, Kite Pharwas
CAT-T cell therapy, under clinical trial, showed
results of The chart and table below shows the
year-on-year growth of the global oncology drugs
market during 2017 - 2021.
Drivers of the Market Restraints on the Market
7
Oncology Drugs Market Segmentation
The chart and table below shows the split of the
oncology drugs market in 2017.
Others include Kaposi Sarcoma, AIDS-Related
Lymphoma, Anal Cancer, Bone Cancer,
Retinoblastoma, Testicular Cancer, Hepatocellular
(Liver) Cancer, Mouth Cancer, Neuroblastoma. The
total market value for oncology drugs was X
billion in 2017. The markets that are covered
include Blood Cancer, Breast Cancer, Cervical
Cancer, Lung Cancer, Colorectal Cancer, Non-Small
Cell Lung Cancer, Prostate Cancer, Kidney Cancer,
Gastric Cancer, Brain Tumor, Pancreatic
Cancer, Skin Cancer, Ovarian Cancer, Bladder
Cancer, Thyroid Cancer, and Others. Blood Cancer
Drugs was the x largest segment in the oncology
drugs market with X share of the market. The
market value for the blood cancer was x billion
in 2017. Breast Cancer Drugs made up around X
share of the market. The market value for the
breast cancer drugs was x billion in 2017.
8
Oncology Drugs Market Regional And Country
Analysis
The Asia Pacific was the x largest region in the
oncology drugs market in 2017, oncology drugs for
X billion or X market share. North America was
the x largest region oncology drugs for X
billion or X market share. Europe was the x
largest region oncology drugs for X billion or
X market share.
9
Oncology Drugs Market Competitive Landscape
The leading competitors in the global oncology
drugs market are F. Hoffmann-La Roche Ltd,
Novartis AG, Gilead Sciences Inc., Bayer AG,
Takeda Pharmaceuticals. The chart and table below
displays the percentage market share of the top
players in the oncology drugs market industry.
F. Hoffmann-La Roche Ltd. generated revenues of
XX billion for the financial year 2016, an XX
increase from the previous year. Novartis AG
generated revenues of XX billion for the
financial year 2016, an XX decrease from the
previous year. Gilead Sciences, Inc. generated
revenues of XX billion for the financial year
2016, an XX decrease from the previous
year. Bayer AG generated revenues of XX billion
for the financial year 2016, an XX increase from
the previous year. Takeda Pharmaceuticals
generated revenues of XX billion for the
financial year 2015, an XX increase from the
previous year.
10
Johnson Johnson generated revenues of XX
billion for the financial year 2016, an XX
increase from the previous year. Pfizer Inc.
generated revenues of XX billion for the
financial year 2016, an 5XX increase from the
previous year. Boehringer Ingelheim GmbH
generated revenues of XX billion for the
financial year 2016, an XX increase from the
previous year. Eli Lilly And Company generated
revenues of XX billion for the financial year
2016, an XX increase from the previous
year. Otsuka Pharmaceutical Co., Ltd. generated
revenues of XX billion for the financial year
2016, an XX decrease from the previous
year. Company Profile F.Hoffmann-La Roche
Overview Roche was the X largest competitor in
the oncology drugs market in 2017 with XX share
of the market. It is a multinational healthcare
company that focuses on developing medicines and
diagnostics. The company was founded in 1896 and
is headquartered in Basel, Switzerland. Products
and Services The company operates through the
following divisions The Pharmaceutical division
develops, The Diagnostics division
manufactures Strategy RoÐhes gro?th strateg?
aiws at increasing revenues from its laboratory
business by introducing new medicines into the
market. In 2016, the company launched four new
medicines
11
Financial Performance F.Hoffmann-La RoÐhes
PharwaÐeutiÐal diisioY, iYoled iY oYÐolog?
drugs manufacturing, generated revenues of CHF XX
billion (XX billion) for the financial year
2016, a XX increase from the previous year. The
company had a market Novartis Overview Products
and Services Strategy Financial
Performance Gilead Sciences, Inc. Overview Produ
cts and Services Strategy Financial
Performance Bayer AG Overview Products and
Services Strategy Financial Performance
12
Takeda Pharmaceuticals Overview Products and
Services Strategy Financial Performance